Novartis Novel STAMP Inhibitor Passes First Phase III Test In CML

Asciminib Could Be New Option For Resistant Patients

 
• By Alexandra Shimmings
Blocks_Stairs
New Therapy For Advanced Patients • Source: Shutterstock

More from Clinical Trials

More from R&D